Brinks Co (BCO) · Oct 8, 2026 · Acquisition

Brink’s acquisition clears UK remedy hurdle, but sale still looms

Remedy accepted in principle — CMA acceptance in principle; NoteMachine/TestLink UK divestiture still required

Brink’s acquisition of NCR Atleos clears a key UK regulatory hurdle, but the required NoteMachine/TestLink sale still must close.

Brink’s is pursuing a roughly $6.6 billion acquisition of NCR Atleos to combine its cash-logistics network with Atleos’ ATM-management and ATM-as-a-Service operations, with the strategic case built around broader recurring revenue and $200 million of annual cost synergies. This filing advances that deal, but does not clear it. The UK regulator has accepted Brink’s proposed remedy in principle, removing the immediate threat of a Phase 2 investigation if Brink’s completes the required divestiture. 〔0〕

The remedy was already becoming the expected path, so the surprise is limited. Brink’s had disclosed on September 30, 2026 that the UK review had identified competition concerns and that a sale process for NoteMachine/TestLink UK was progressing. The new information is that the CMA considers the proposed remedy acceptable in principle—not that the regulatory issue has disappeared.

The strategic economics are presented as intact, but execution risk remains concentrated in the sale. Management says the UK divestiture was already contemplated in its transaction metrics and does not reduce the targeted $200 million of annual run-rate cost synergies within three years of closing. 〔1〕 That preserves the headline deal thesis on paper, but Brink’s still needs to select an acceptable buyer and finish the disposal quickly enough to avoid a Phase 2 referral.

Bottom line: This is a modestly positive regulatory step for the NCR Atleos acquisition, not final clearance. It reduces one obstacle while shifting the immediate burden to completing the UK divestiture.

What to watch next

Select buyer and complete the UK divestiture

Original filing on SEC EDGAR

More Brinks Co news

Brink’s acquisition clears UK remedy hurdle, but sale still looms | BCO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.